Intergroupe Francophone De Cancerologie Thoracique

This study tested the drug durvalumab in 50 people with advanced stage IV non-small cell lung cancer who were in poor health (ECOG 2-3) and had not received prior treatment. The goal was to see if the drug could control the cancer with acceptable side effects. The approach uses t…

This study looked at 265 people with advanced non-small cell lung cancer whose tumors had a protein called PD-L1. After 6 months of treatment with two immunotherapy drugs (nivolumab and ipilimumab), half the patients stopped treatment and were watched, while the other half contin…